Greenland Mines (NASDAQ: GRML) is executing a strategic transformation into a focused rare earths and critical minerals company, with plans to spin off its biotechnology division in the fourth quarter of 2026. The announcement comes as the company achieves key milestones, including Nasdaq listing compliance and the completion of its Sarfartoq project acquisition.
Nasdaq has formally approved the company's application relating to its March 2026 transaction, resolving prior deficiencies and bringing Greenland Mines into full compliance with listing requirements. This regulatory clearance removes overhang and allows the company to proceed with its corporate plans without listing-related uncertainties.
The company completed its acquisition of the Sarfartoq project on Sept. 1 following approval by the Government of Greenland. Sarfartoq is a neodymium-praseodymium (NdPr) rare earths project in southwest Greenland, which is central to the company's strategy of building exposure to magnet metals essential for electric vehicles and renewable energy.
An independent S-K 1300 Initial Assessment for the ST1 deposit estimated a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. These robust economics underscore the project's potential to become a significant supplier of NdPr oxide, a critical input for permanent magnets used in various clean energy technologies.
Greenland Mines said planned annual NdPr oxide production from ST1 would equal approximately 34% of current NdPr oxide refining outside China based on 2025 consumption levels during each of the project's nine scheduled operating years. This positions the company as a key player in the Western supply chain for rare earths, reducing dependence on Chinese processing.
The company is also reshaping its board, with Riad El-Dada and Dr. Shalom Hirschman stepping down and capital markets veteran Jason Hawkins joining. The board changes are aimed at strengthening governance and capital markets expertise as Greenland Mines advances Sarfartoq and its Skaergaard palladium-gold-platinum project.
The spin-off of the biotech division, which includes Klotho's KLTO-202 primary indication for ALS, will allow the mining division to focus on its core critical minerals business. This separation is expected to unlock value for shareholders by enabling each division to be valued independently.
For more information on the full press release, visit https://ibn.fm/QN1U9.
The latest news and updates relating to GRML are available in the company's newsroom at https://ibn.fm/GRML.
